Primary malignant melanoma of the cervix. Case report

Revista Colombiana de Cancerología

View Publication Info
 
 
Field Value
 
Title Primary malignant melanoma of the cervix. Case report
Melanoma primario de cuello uterino. Reporte de caso
 
Creator Caicedo, Lina
Santana, Diana
Calderón, Pedro
 
Subject cervix uteri; primary malignant melanoma of the cervix; immunotherapy; diagnosis; treatment; uterine hemorrhage; immunohistochemistry
cuello uterino; melanoma maligno primario de cuello uterino; inmunoterapia; diagnostico; tratamiento; hemorragia uterina; inmunohistoqumica
 
Description Summary
Primary mucosal melanoma accounts for 1% of all cancers. Its location in the cervix is rare, and less than 100 cases have been reported in the literature to date. Data related to its staging and treatment are scarce, and it has a poor prognosis, with survival rates of 10% at 5 years. We present the clinical case of an 82-year-old patient with vaginal bleeding, with evidence of a melanotic lesion of the cervix. The biopsy of the lesion reported a poorly differentiated malignant tumor involvement, with an immune profile confirming malignant melanoma. Extension studies performed showed no distant metastatic disease. The case was presented in a multidisciplinary oncological gynecology meeting, indicating treatment with exclusive external pelvic radiotherapy with palliative intent for symptom control, considering patient’s age, comorbidities, and ECOG 3 (Eastern Cooperative Oncology Group) functional status. After 10 months of follow-up, the patient died.
 
RESUMEN
El melanoma primario de mucosas representa el 1% de todos los cánceres, la presentación en cuello uterino es rara, existen pocos casos reportados en la literatura, los datos son limitados de estatificación y tratamiento, su pronostico es pobre. Presentamos un caso clínico de paciente de 82 años con diagnostico de melanoma primario de cuello uterino, el diagnóstico patológico se realizó con inmunohistoquimica HMB-45 y S100 positivas en tejido tumoral
METODOS
Reporte de un caso clínico de paciente de 82 años con diagnostico de melanoma primario de cuello uterino
RESULTADOS
El melanoma de mucosas es más frecuente en pacientes con edad avanzada mayores de 60 años. La etiología de esta entidad no es clara, solo hay hipótesis de su origen, se presenta con síntomas inespecíficos de flujo o hemorragia uterina, macroscópicamente se presenta como lesión exofítica, pigmentada en cuello uterino, es necesario para diagnostico la inmunohistoquimica, para su tratamiento se plantea el abordaje quirúrgico como la mejor estrategia, hay reportes de esquemas de quimioterapia, la radioterapia queda reservada para control paliativo sintomático. Hay estudios para el uso de inmunoterapia en el manejo de esta patología con resultados poco prometedores. La presentación en cuello uterino es agresiva y su pronostico es pobre por la rápida diseminación a los pocos meses del diagnostico
CONCLUSION
El melanoma primario de cuello uterino es una entidad rara, aun sin conocimiento claro de su origen, con escasa evidencia sobre su manejo y con un pobre pronostico de supervivencia a corto plazo 
 
 
Publisher Instituto Nacional de Cancerología
 
Date 2021-02-08
 
Type info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
 
Format application/pdf
 
Identifier https://www.revistacancercol.org/index.php/cancer/article/view/104
10.35509/01239015.104
 
Source Revista Colombiana de Cancerología; Vol. 25 No. 1 (2021)
Revista Colombiana de Cancerología; Vol. 25 Núm. 1 (2021)
Revista Colombiana de Cancerología; v. 25 n. 1 (2021)
2346-0199
0123-9015
 
Language spa
 
Relation https://www.revistacancercol.org/index.php/cancer/article/view/104/533
/*ref*/Patrick RJ, Fenske NA, Messina JL. Primary mucosal melanoma. J Am Acad Dermatol. 2007;56(5):828-34. https://doi.org/10.1016/j.jaad.2006.06.017 2. Lim KH, Tay SK, Ng AXH, Mantoo S. Primary Melanoma of the Uterine Cervix: A Case Report, with Key Points on Recognition and Pathological Diagnosis. J Low Genit Tract Dis. 2017;21(1):e1-4. https://doi.org/10.1097/LGT.0000000000000264 3. Pusceddu S, Bajetta E, Carcangiu ML, Formisano B, Ducceschi M, Buzzoni R. A literature overview of primary cervical malignant melanoma: An exceedingly rare cancer. Crit Rev Oncol Hematol. 2012;81(2):185-95. https://doi.org/10.1016/j.critrevonc.2011.03.008 4. McLaughlin CC, Wu XC, Jemal A, Martin HJ, Roche LM, Chen VW. Incidence of noncutaneous melanomas in the U.S. Cancer. 2005;103(5):1000-7. https://doi.org/10.1002/cncr.20866 5. Zamiati S, Sahraoui S, Jabri L, Louahlia S, Sqalli S, Kahlain A. Mélanome malin primitif du col utérin: À propos d’un cas avec revue de la littérature. Gynecol Obstet Fertil. 2001;29(5):381-5. https://doi.org/10.1016/S1297-9589(01)00148-5 6. Myriokefalitaki E, Babbel B, Smith M, Ahmed AS. Primary malignant melanoma of uterine cervix FIGO IIa1: A case report with 40months ongoing survival and literature review. Gynecol Oncol Reports. 2013;5:52-4. https://doi.org/10.1016/j.gynor.2013.04.004 7. Deshpande AH, Munshi MM. Primary malignant melanoma of the uterine cervix: Report of a case diagnosed by cervical scrape cytology and review of the literature. Diagn Cytopathol. 2001;25(2):108-11. https://doi.org/10.1002/dc.2014 8. Cetinkaya K, Benzer E, Dervisoglu H. Primary mucosal malignant melanoma of the cervix: Case report and review of the literature. Tumori. 2015;101(5):e147-50. https://doi.org/10.5301/tj.5000304 9. Jin B, Goldsmith A, Budev H, Al-Abbadi M. Primary melanoma of the uterine cervix after supracervical hysterectomy: A case report. Acta Cytol. 2007;51(1):86-8. https://doi.org/10.1159/000325690 10. Gupta S, Sodhani P, Jain S. Primary malignant melanoma of uterine cervix: A rare entity diagnosed on fine needle aspiration cytology - Report of a case. Cytopathology. 2003;14(3):153-6. https://doi.org/10.1046/j.1365-2303.2003.00014.x 11. Samper AM. Melanoma de alto riesgo reestadificado con F-18-FDG-PET/CT. Rev Colomb Cancerol. 2014;18(4):202-5. https://doi.org/10.1016/j.rccan.2014.04.004 12. Piura B. Management of primary melanoma of the female urogenital tract. Lancet Oncol. 2008;9(10):973-81. https://doi.org/10.1016/S1470-2045(08)70254-7 13. Nilsson PJ, Ragnarsson-Olding BK. Importance of clear resection margins in anorectal malignant melanoma. Br J Surg. 2010;97(1):98-103. https://doi.org/10.1002/bjs.6784 14. Behtash N, Mousavi A, Tehranian A, Khanafshar N, Hanjani P. Embryonal rhabdomyosarcoma of the uterine cervix: Case report and review of the literature. Gynecol Oncol. 2003;91(2):452-5. https://doi.org/10.1016/S0090-8258(03)00539-0 15. Hutchinson F, Cancer S, Alliance C. Treatment of Metastatic Melanoma : An Overview - Cancer Network Treatment of Metastatic Melanoma : An Overview Treatment of Metastatic Melanoma : An Overview - Cancer Network. Network. 2010;23(6):1-7. 16. Oliva ICG, Alqusairi R. Immunotherapy for Melanoma. In: Naing A, Hajjar J (Editiors). Immunotherapy. Second Edition. Springer; 2018. p. 43-63. https://doi.org/10.1007/978-3-030-02505-2_2 17. Atkins MB, Lotze MT, Dutcher JP, Fisher RI, Weiss G, Margolin K, et al. High-Dose Recombinant Interleukin 2 Therapy for Patients With Metastatic Melanoma: Analysis of 270 Patients Treated Between 1985 and 1993. J Clin Oncol. 1999;17(7):2105-16. https://doi.org/10.1200/JCO.1999.17.7.2105 18. Wei SC, Levine JH, Cogdill AP, Zhao Y, Andrews MC, Sharma P, et al. Distinct cellular mechanisms underlie anti-CTLA-4 and anti-PD-1 checkpoint blockade. Cell. 2018;170(6):1120-33. https://doi.org/10.1016/j.cell.2017.07.024 19. Sosman JA, Haanen JB, Gonzalez R, Robert C, Ph D, Schadendorf D, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711-23. https://doi.org/10.1056/NEJMoa1003466 20. Lin GG, Scott JG. Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway. Trends Mol Med. 2015;21(1):24-33. https://doi.org/10.1016/j.molmed.2014.10.009 21. Hodi S, Chesney J, Pavlick AC, Robert C, Grossmann KF, Mcdermott DF, et al. Two-year overall survival rates from a randomised phase 2 trial evaluating the combination of nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma. Lancet Oncol. 2016;17(11):1558-68. https://doi.org/10.1016/S1470-2045(16)30366-7 22. Schachter J, Ribas A, Long GV, Arance A, Grob JJ, Mortier L, et al. Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006). Lancet. 2017;390(10105):1853-62. https://doi.org/10.1016/S0140-6736(17)31601-X 23. Flaherty KT, Infante JR, Daud A, Gonzalez R, Kefford RF, Sosman J, et al. Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations. N Engl J Med. 2013;367(18):1694-703. https://doi.org/10.1056/NEJMoa1210093 24. Carvajal RD, Antonescu CR, Wolchok JD, Chapman PB, Roman RA, Teitcher J, et al. KIT as a therapeutic target in metastatic melanoma. JAMA. 2011;305(22):2327–34. https://doi.org/10.1001/jama.2011.746 25. Hodi FS, Corless CL, Giobbie-Hurder A, Fletcher JA, Zhu M, Marino-Enriquez A, et al. Imatinib for melanomas harboring mutationally activated or amplified kit arising on mucosal, acral, and chronically sun-damaged skin. J Clin Oncol. 2013;31(26):3182-90. https://doi.org/10.1200/JCO.2012.47.7836 26. Tacastacas JD, Bray J, Cohen YK, Arbesman J, Kim J, Koon HB, et al. Update on primary mucosal melanoma. J Am Acad Dermatol. 2014;71(2):366-75. https://doi.org/10.1016/j.jaad.2014.03.031
 
Rights Derechos de autor 2021 Revista Colombiana de Cancerología
 

Contact Us

The PKP Index is an initiative of the Public Knowledge Project.

For PKP Publishing Services please use the PKP|PS contact form.

For support with PKP software we encourage users to consult our wiki for documentation and search our support forums.

For any other correspondence feel free to contact us using the PKP contact form.

Find Us

Twitter

Copyright © 2015-2018 Simon Fraser University Library